Key Takeaways
- • Private equity firms have gained increasing control of U.S. health care infrastructure, with mounting evidence suggesting PE involvement generally results in curtailed access to affordable, high-quality care for vulnerable populations.
- • PE investment disproportionately harms rural populations, older people, low-income communities, and marginalized racial and ethnic groups—populations already struggling with care affordability and system navigation—threatening progress in health equity.
- • While PE investors claim to improve efficiency, raise capital, and leverage economies of scale, evidence demonstrates that excessively high returns often come at the expense of patient access and care quality.
- • Health economists argue that states can mitigate PE-driven healthcare harm through regulatory monitoring of operational and accounting practices, with enforcement mechanisms to punish entities that compromise access to affordable, high-quality care.
Summary
Private equity firms have substantially increased their control over U.S. health care infrastructure in recent years, according to a February 2026 perspective published in the New England Journal of Medicine. The article, authored by Ruqaiijah Yearby of Temple University's Beasley School of Law and Marcella Alsan, a health economist at Stanford University, examines the implications of this trend for health equity—defined as ensuring all individuals have a fair opportunity for optimal health outcomes.
The research challenges the narrative commonly advanced by PE investors that their involvement improves operational efficiency, raises necessary capital, and leverages economies of scale. Instead, mounting evidence indicates that PE practices in healthcare have generally produced the opposite effect: reduced access to affordable, high-quality care. Alsan notes that "although PE has extended financing to under-resourced health care systems and generated profits for partners, it has done so at a steep price." The financial gains accruing to PE partners appear concentrated while the costs are distributed across patient populations most vulnerable to disruption.
The health equity implications are particularly acute for specific demographic groups. According to the analysis, the negative consequences of PE involvement disproportionately affect rural populations, elderly patients, low-income communities, and members of marginalized racial and ethnic groups—populations that already face structural barriers to affordable care and systemic navigation challenges. These populations lack the resources or flexibility to absorb reduced access or quality deterioration.
The authors argue that without robust regulatory intervention, PE practices will continue reshaping healthcare in ways detrimental to patients and clinicians. They recommend that states implement monitoring mechanisms to track PE's operational and accounting practices, with enforcement authority to sanction entities that compromise access to affordable, high-quality care. This regulatory framework would serve as a counterweight to PE's financial optimization strategies that may prioritize shareholder returns over patient outcomes and population health.
The research challenges the narrative commonly advanced by PE investors that their involvement improves operational efficiency, raises necessary capital, and leverages economies of scale. Instead, mounting evidence indicates that PE practices in healthcare have generally produced the opposite effect: reduced access to affordable, high-quality care. Alsan notes that "although PE has extended financing to under-resourced health care systems and generated profits for partners, it has done so at a steep price." The financial gains accruing to PE partners appear concentrated while the costs are distributed across patient populations most vulnerable to disruption.
The health equity implications are particularly acute for specific demographic groups. According to the analysis, the negative consequences of PE involvement disproportionately affect rural populations, elderly patients, low-income communities, and members of marginalized racial and ethnic groups—populations that already face structural barriers to affordable care and systemic navigation challenges. These populations lack the resources or flexibility to absorb reduced access or quality deterioration.
The authors argue that without robust regulatory intervention, PE practices will continue reshaping healthcare in ways detrimental to patients and clinicians. They recommend that states implement monitoring mechanisms to track PE's operational and accounting practices, with enforcement authority to sanction entities that compromise access to affordable, high-quality care. This regulatory framework would serve as a counterweight to PE's financial optimization strategies that may prioritize shareholder returns over patient outcomes and population health.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.